NIAID DMID Topic 131 (Phase II) "Development of Bacteriophage for Treatment of Mycobacterial Infections"
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $1,500,000 to $3,000,000
- Set-aside
- Total Small Business
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health, through NIAID's DMID, forecasts a new requirement for Phase II preclinical research and development of therapeutic bacteriophage products targeting mycobacteria under Research Topic 131, with an estimated solicitation release of September 1, 2026 and an estimated award of October 1, 2026. The work emphasizes preclinical development of Non-Tuberculous Mycobacterial (NTM) infections, including antibiotic-resistant mycobacterial infections, and continues Phase I activities under a contract that ended in September 2025. Phase II is structured as a milestone-driven period, and the statement of work is attached to the forecast.
The estimated award value range is $1.5 million to $3 million, and the requirement is set aside for Total Small Business under NAICS 541715. Both estimated dates precede this forecast's November 14, 2026 posting date. Points of contact are James Boyce (jim.boyce@nih.gov, Department of HHS) and Contracting Officer Callie Prassinos (callie.prassinos@nih.gov, +12406695155, NIH).
Forecast text
NIAID DMID Topic 131 (Phase II) "Development of Bacteriophage for Treatment of Mycobacterial Infections"
The goal for Research Topic 131 is to provide support for preclinical research and development of
therapeutic phage products that target mycobacteria. Within this scope, special emphasis is placed on preclinical development of Non-Tuberculous Mycobacterial (NTM) infections; and including antibiotic-resistant mycobacterial infections. This is a continuation of a Phase I contract that ended in September 2025. If not continued in a planned milestone driven Phase II period, the investment in discoveries made during the Phase I period could languish or be lost. Phase II activities are described in the attached statement of work and include continuation of Phase I activities.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast